We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > JS016

News List

Lilly Begins Study for Second Potential COVID-19 Antibody Treatment americanpharmaceuticalreview
June 17, 2020
Eli Lilly and Company announced its partner Junshi Biosciences has dosed the first healthy volunteer in a study of a potential neutralizing antibody treatment designed to fight COVID-19.
Second of Lilly’s COVID-19 neutralising antibodies begins Phase I trials europeanpharmaceuticalreview
June 11, 2020
The first patient has been dosed in the Chinese Phase I trial of JS016 in healthy people who do not have a COVID-19 diagnosis.
Lilly and Junshi Biosciences Initiate Phase I COVID-19 Trials contractpharma
June 10, 2020
Studies will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of JS016 in healthy participants who have not been diagnosed with COVID-19.
Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment prnewswire
June 09, 2020
Eli Lilly and Company announced its partner Junshi Biosciences has dosed the first healthy volunteer in a study of a potential neutralizing antibody treatment designed to fight COVID-19.
Shanghai Junshi Biosciences starts human tests for coronavirus antibody drug expresspharma
June 08, 2020
The experimental drug, JS016, is also expected to begin human study in the US in the second quarter of this year, through collaboration with Eli Lilly and Co.